Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer (Q33780751)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer |
scientific article |
Statements
1 reference
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer (English)
1 reference
Kae Hashimoto
1 reference
Shan Man
1 reference
Ping Xu
1 reference
William Cruz-Munoz
1 reference
Terence Tang
1 reference
Rakesh Kumar
1 reference
Robert S Kerbel
1 reference
6 April 2010
1 reference
1 reference
996-1006
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference